Scurvy and stroke - is there an association?

Scurvy and stroke: is there an association? Med J Aust (2011) 0.75

Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol (2013) 2.52

Guillain-Barré syndrome: an update. J Clin Neurosci (2009) 2.46

Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol (2009) 2.20

Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 2.08

Botulinum toxin modulates cortical maladaptation in post-stroke spasticity. Muscle Nerve (2013) 2.00

Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain (2008) 1.94

Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2011) 1.75

Segmental facial anhidrosis and tonic pupils with preserved deep tendon reflexes: a novel autonomic neuropathy. J Neuroophthalmol (2005) 1.63

Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol (2011) 1.59

Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol (2011) 1.55

Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol (2008) 1.54

Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.52

Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain (2009) 1.50

Changes in human sensory axonal excitability induced by an ischaemic insult. Clin Neurophysiol (2008) 1.49

Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.49

Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain (2006) 1.47

Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clin Neurophysiol (2010) 1.47

FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry (2009) 1.44

Riluzole: a glimmer of hope in the treatment of motor neurone disease. Med J Aust (2005) 1.42

Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clin Neurophysiol (2010) 1.41

Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve (2005) 1.37

Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol (2009) 1.37

Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin (2014) 1.36

Neurotoxic marine poisoning. Lancet Neurol (2005) 1.33

Motor neuron dysfunction in frontotemporal dementia. Brain (2011) 1.31

Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve (2007) 1.30

Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol (2009) 1.27

Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist (2011) 1.22

Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol (2006) 1.22

Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr Mol Med (2009) 1.19

Fatigue in multiple sclerosis: mechanisms and management. Clin Neurophysiol (2010) 1.18

Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2012) 1.18

Altered nerve excitability properties in established diabetic neuropathy. Brain (2005) 1.17

Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve (2006) 1.17

Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One (2012) 1.15

Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry (2012) 1.14

Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain (2008) 1.10

FOSMN syndrome: novel insight into disease pathophysiology. Neurology (2012) 1.10

How common are behavioural changes in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2010) 1.09

Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum. Amyotroph Lateral Scler (2012) 1.08

Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 1.05

Changes in human sensory axonal excitability induced by focal nerve compression. J Physiol (2010) 1.04

Altered motor nerve excitability in end-stage kidney disease. Brain (2005) 1.02

Nerve function and dysfunction in acute intermittent porphyria. Brain (2008) 1.00

Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res (2006) 1.00

Engaging in patient decision-making in multidisciplinary care for amyotrophic lateral sclerosis: the views of health professionals. Patient Prefer Adherence (2012) 1.00

Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer (2012) 0.98

Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 0.98

INSPIRATIonAL--INSPIRAtory muscle training in amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2009) 0.96

Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry (2009) 0.95

Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain (2010) 0.95

Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol (2014) 0.94

Threshold behaviour of human axons explored using subthreshold perturbations to membrane potential. J Physiol (2008) 0.94

Axonal changes in spinal cord injured patients distal to the site of injury. Brain (2007) 0.94

Neurological complications of chronic kidney disease. Nat Rev Neurol (2009) 0.93

Has potassium been prematurely discarded as a contributing factor to the development of uraemic neuropathy? Nephrol Dial Transplant (2004) 0.93

Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain (2013) 0.92

Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One (2011) 0.92

Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry (2013) 0.92

Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. Amyotroph Lateral Scler (2011) 0.91

Assessment of disease progression in motor neuron disease. Lancet Neurol (2005) 0.91

Congenital myasthenic syndromes. J Clin Neurosci (2008) 0.90

Assessing the accuracy of a combination of clinical tests for identifying carpal tunnel syndrome. J Clin Neurosci (2009) 0.90

Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes. Neurology (2013) 0.90

The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol (2010) 0.89

Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr (2012) 0.89

Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle Nerve (2010) 0.88

Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst (2008) 0.88

Puffer fish poisoning: a potentially life-threatening condition. Med J Aust (2002) 0.88

Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002). J Clin Neurosci (2006) 0.87

Predicting a positive response to intravenous immunoglobulin in isolated lower motor neuron syndromes. PLoS One (2011) 0.87

The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Res (2009) 0.87

The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol (2013) 0.86

The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics (2015) 0.86

Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Exp Neurol (2009) 0.86

Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology (2013) 0.85

Wernicke's encephalopathy presenting with upbeating nystagmus. J Clin Neurosci (2002) 0.85

Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis. Muscle Nerve (2014) 0.85

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs (2010) 0.85

The relationship between cortical and spinal hyperexcitability and clinical disease severity in stiff-man syndrome. Parkinsonism Relat Disord (2012) 0.85

Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney disease. PLoS One (2013) 0.85

Cortical dysfunction underlies disability in multiple sclerosis. Mult Scler (2011) 0.84

The pain with platinum: oxaliplatin and neuropathy. Eur J Cancer (2007) 0.84

In vivo loss of slow potassium channel activity in individuals with benign familial neonatal epilepsy in remission. Brain (2012) 0.84

Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain (2011) 0.84

Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma. J Clin Neurosci (2006) 0.84

Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis. J Neurol (2015) 0.84

Motor cortex excitability in acute cerebellar infarct. Cerebellum (2013) 0.83

Ischaemic sensitivity of axons in carpal tunnel syndrome. J Peripher Nerv Syst (2009) 0.83

Maladaptation of cortical circuits underlies fatigue and weakness in ALS. Amyotroph Lateral Scler (2011) 0.83

Plasticity of lower limb motor axons after cervical cord injury. Clin Neurophysiol (2008) 0.83

Is there a case for diaphragm pacing for amyotrophic lateral sclerosis patients? Amyotroph Lateral Scler (2012) 0.82

Hyperexcitability and amyotrophic lateral sclerosis. Neurology (2012) 0.82

Nerve conduction studies. Aust Fam Physician (2011) 0.82

Activity-dependent conduction failure: molecular insights. J Peripher Nerv Syst (2011) 0.82

Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease. Brain (2006) 0.82

Focal and generalized peripheral nerve dysfunction in spinal cord-injured patients. J Clin Neurophysiol (2006) 0.81

Motor neuron disease-frontotemporal dementia: a clinical continuum. Expert Rev Neurother (2015) 0.81

Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis. Mult Scler (2012) 0.81

The realm of neurology--past, present and future. J Neurol Neurosurg Psychiatry (2011) 0.81